UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 69

Sortiert nach

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

The Lancet (British edition), 2015-06, Vol.385 (9987), p.2606-2615

2015

Link zum Volltext

Verfügbarkeit prüfen

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study

Journal of acquired immune deficiency syndromes (1999), 2020-07, Vol.84 (3), p.323

2020

Link zum Volltext

Verfügbarkeit prüfen

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults

Journal of acquired immune deficiency syndromes (1999), 2016-11, Vol.73 (3), p.294

2016

Link zum Volltext

Verfügbarkeit prüfen

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

Journal of acquired immune deficiency syndromes (1999), 2017-02, Vol.74 (2), p.193

2017

Link zum Volltext

Verfügbarkeit prüfen

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate

Open forum infectious diseases, 2020-01, Vol.7 (1), p.ofz472-ofz472

2020

Link zum Volltext

Verfügbarkeit prüfen

Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial

EClinicalMedicine, 2021-06, Vol.36, p.100893, Article 100893

2021

Link zum Volltext

Verfügbarkeit prüfen

Interaction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2005-12, Vol.49 (12), p.4903-4910

2005

Link zum Volltext

Verfügbarkeit prüfen

The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States

Annals of epidemiology, 2018-12, Vol.28 (12), p.841-849

2018

Link zum Volltext

Verfügbarkeit prüfen

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide

EBioMedicine, 2016-11, Vol.13 (C), p.321-327

2016

Link zum Volltext

Verfügbarkeit prüfen

Gender Parity in Clinical PrEP Trials

The New England journal of medicine, 2019-12, Vol.381 (26), p.2585

2019

Link zum Volltext

Verfügbarkeit prüfen

Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017

Annals of epidemiology, 2018-12, Vol.28 (12), p.833-840

2018

Link zum Volltext

Verfügbarkeit prüfen

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study

Journal of acquired immune deficiency syndromes (1999), 2014-09, Vol.67 (1), p.52

2014

Link zum Volltext

Verfügbarkeit prüfen

Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012–2016

Clinical infectious diseases, 2020-12, Vol.71 (12), p.3144-3151

2020

Link zum Volltext

Verfügbarkeit prüfen

Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018

Annals of epidemiology, 2020-05, Vol.45, p.24-31.e3

2020

Link zum Volltext

Verfügbarkeit prüfen

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

Journal of acquired immune deficiency syndromes (1999), 2016-04, Vol.71 (5), p.530

2016

Link zum Volltext

Verfügbarkeit prüfen

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results

Journal of acquired immune deficiency syndromes (1999), 2017-06, Vol.75 (2), p.211

2017

Link zum Volltext

Verfügbarkeit prüfen

Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial

Annals of internal medicine, 2013-07, Vol.159 (2), p.86

2013

Link zum Volltext

Verfügbarkeit prüfen

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

Journal of acquired immune deficiency syndromes (1999), 2015-08, Vol.69 (4), p.439

2015

Link zum Volltext

Verfügbarkeit prüfen

Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks

Journal of clinical virology, 2018-06, Vol.103, p.37-42

2018

Link zum Volltext

Verfügbarkeit prüfen

Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions

Annals of epidemiology, 2020-04, Vol.44, p.16-30

2020

Link zum Volltext

Verfügbarkeit prüfen

Gender Parity in Clinical PrEP Trials

The New England journal of medicine, 2019-12, Vol.381 (26), p.2584-2586

2019

Link zum Volltext

Verfügbarkeit prüfen

Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues

Journal of antimicrobial chemotherapy, 2017-06, Vol.72 (6), p.1731-1740

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(68)
Buchkapitel
(1)

Sprache

Englisch
(69)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study

Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study

Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults

A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected Adults

Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate

Safety and Pharmacokinetics of a Tenofovir Alafenamide Fumarate-Emtricitabine based Oral Antiretroviral Regimen for Prevention of HIV Acquisition in Women: A Randomized Controlled Trial

Interaction of Ritonavir-Boosted Tipranavir with Loperamide Does Not Result in Loperamide-Associated Neurologic Side Effects in Healthy Volunteers

The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis–to-need ratio in the fourth quarter of 2017, United States

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide

Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Gender Parity in Clinical PrEP Trials

Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017

Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study

Evidence of an Association of Increases in Pre-exposure Prophylaxis Coverage With Decreases in Human Immunodeficiency Virus Diagnosis Rates in the United States, 2012–2016

Policy- and county-level associations with HIV pre-exposure prophylaxis use, the United States, 2018

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results

Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study

Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks

Methods for county-level estimation of pre-exposure prophylaxis coverage and application to the U.S. Ending the HIV Epidemic jurisdictions

Gender Parity in Clinical PrEP Trials

Weight changes and adverse pregnancy outcomes with dolutegravir- and tenofovir alafenamide fumarate-containing antiretroviral treatment regimens during pregnancy and postpartum

Single-dose pharmacokinetics of tenofovir alafenamide and its active metabolite in the mucosal tissues

Suchergebnisse filtern